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Abstract
Background: The immunotherapy using dendritic cells (DCs) against different varieties
of cancer is an approach that has been previously explored which induces a specific
immune response. This work presents a mathematical model of DCs immunotherapy
for melanoma in mice based on work by Experimental Immunotherapy Laboratory of
the Medicine Faculty in the Universidad Autonoma de Mexico (UNAM).
Method: The model is a five delay differential equation (DDEs) which represents a
simplified view of the immunotherapy mechanisms. The mathematical model takes
into account the interactions between tumor cells, dendritic cells, naive cytotoxic T
lymphocytes cells (inactivated cytotoxic cells), effector cells (cytotoxic T activated
cytotoxic cells) and transforming growth factor β cytokine (TGF − β). The model is
validated comparing the computer simulation results with biological trial results of the
immunotherapy developed by the research group of UNAM.
Results: The results of the growth of tumor cells obtained by the control
immunotherapy simulation show a similar amount of tumor cell population than the
biological data of the control immunotherapy. Moreover, comparing the increase of
tumor cells obtained from the immunotherapy simulation and the biological data of
the immunotherapy applied by the UNAM researchers obtained errors of
approximately 10%. This allowed us to use the model as a framework to test
hypothetical treatments. The numerical simulations suggest that by using more doses
of DCs and changing the infusion time, the tumor growth decays compared with the
current immunotherapy. In addition, a local sensitivity analysis is performed; the results
show that the delay in time “τ ”, the maximal growth rate of tumor “r” and the maximal
efficiency of tumor cytotoxic cells rate “aT ” are the most sensitive model parameters.
Conclusion: By using this mathematical model it is possible to simulate the growth of
the tumor cells with or without immunotherapy using the infusion protocol of the
UNAM researchers, to obtain a good approximation of the biological trials data.
It is worth mentioning that by manipulating the different parameters of the model the
effectiveness of the immunotherapy may increase. This last suggests that different
protocols could be implemented by the Immunotherapy Laboratory of UNAM in order
to improve their results.
Keywords: Mathematical model, Cancer, Melanoma, Immunotherapy, Dendritic cell,
TGF − β cytokine
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Background
Melanoma is a dangerous form of skin cancer and its prevalence is increasing at a dra-
matic rate worldwide [1, 2]. In the last decades, there have been significant advances in the
treatments for early stagemelanomawith a high survival rate but not for the latter invasive
stage where treatments are limited [3, 4]. One of these treatments is the immunotherapy
for melanoma which activates the immune response and stimulates the mechanisms of
defence against cancer [3, 5, 6].
The immunotherapy used the tumor cell property to express antigens than can be
recognized by the immune system and became targets of the tumor-specific T cells
[4, 7, 8]. This is to stimulate and boost the immune response to tumor-specific cells
and not to injure the normal cells using tumor-specific antigens, mature dendritic cells
(DCs), T-cells or cytokines [5, 9]. Lately, the identification of tumor antigens and the
advance in the understanding of the immune system has allowed the development of new
immunotherapies [5].
The antigen-specific immunotherapy with DCs uses the capacity of present antigens
and activates the immune specific response of DCs. Immature DCs in a steady state
located in epithelial and connective tissues have the ability to detect and capture anti-
gens that are found. After capturing the tumor antigens, these mature and transport the
antigen to lymph nodes where they present the tumor antigen to naive T lymphocyte
cells (CD4+ and CD8+ T lymphocytes). These encounters activated CD8+ lymphocytes
proliferating and differentiating into CTLs leaving the lymphoid organs where they were
generated and migrate to eliminate the tumor cells [5, 10].
Tumor cells use the mechanisms of host defense to promote tumor progression, inva-
sion, and dissemination to distant sites. One of these mechanisms is by secreting TGF−β
cytokine which damped the immune response. For example, interfering with the anti-
gen transportation to lymph nodes or affecting the CD4+ and CD8+ effector functions
(proliferation, differentiation, and acquisition of effector molecules) [11, 12].
In this immunotherapy, the DCs taken from the patient were incubated with tumor anti-
gens and adjuvants in vitro and then injected back into the patient. The immunotherapy
is specific because it only eliminates tumor cells and does not injure most normal cells in
patient [5].
There is hope that one of these immunotherapies, the Sipuleucel-T treatment shows
that the personalized treatment with antigen-presenting cells (APCs) could be effi-
cient to extend the life of people suffering from prostate cancer by 31.7% over a 36
month period [13]. For that reason the investigation with dendritic cells is one of the
immunotherapy treatments being studied and improved lately. The research group at
Medicine Faculty of UNAM are developing a immunotherapy using DCs infusion onmice
with melanoma cancer and have up till now prolonged their life by 33% over 34 days [14].
The UNAM researchers incubate the DCs derived from mice bone marrow with
granulocyte-macrophage colony stimulating factor (GM-CFS) to mature the cells and
antigenMAGE−AX peptide which stimulate the immune response before being injected
into the mice. The biological treatment efficiency is measured taking into consideration
the tumor diameters, cytokines modulation (IL-2 and IL-10), the expression of major
histocompatibility complex molecules (MHC) and the survival of the mice.
However, the tumor has not been eradicated and there are still many unanswered
questions about how the immune system interacts with the tumor cells, and which
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components of the immune system play significant roles in responding to immunother-
apy. Actually, they used only one infusion protocol (see Table 1 Protocol 1). This is
applied in all their immune treatments and they are looking for a new infusion protocol
to improve their results.
In this way mathematical models may provide an analytic framework to address ques-
tions and these models can be used both descriptively and predictively for the new
therapies [15, 16]. An example of the success of this type of mathematical models was
performed by Kronik et. al. [17], they developed a personalized mathematical model to
simulate the interaction between allogenic prostate cancer (PCa) whole-cell vaccine and
the immune system in patient. They validate their results with clinical trials tests.
This differs from our work in the sense that we propose amathematical model Ad hoc of
the immunotherapy developed by the research group at Medicine Faculty of UNAM. The
consequences of manipulating some of the parameters associated with a particular treat-
ment is explored; also, this model is used to study hypothetical immunotherapy protocols
and examines the consequences in the growth of the tumor cells population.
Results
Simulation and validation of tumor cells growth
To simulate the tumor cells growth without immunotherapy an initial population of 6∗104
tumor cells to induce melanoma in mice is taken (Table 1) and the parameters listed in
the additional material (see Additional file 1) with the parameter of maximal efficiency of
cytotoxic cells set to 0, i.e. “aT = 0”.
Normalized root mean square error (NRSME) between the real data and the numerical
simulation is obtained, taking into account the measurement time made by the UNAM
researchers (the 7th day after melanoma cell induction and every two days after the 10th
day for a period of 700 hours). The population of the tumor cells in the melanoma tumor
was calculated from the diameters average of tumor melanoma assuming a spheric form
(size of tumor cells equal to 17.4± 0.21µm [18]) .
Figure 1, show the data of real tumor cellular growth and the tumor cellular growth
obtained by the mathematical model. It can be seen that the growth of the tumor is
interrupted at 672 hours because all the surviving mice were sacrificed after the fourth
week.
Given the immunotherapy protocol of the UNAM researchers which administered
three doses of 106 DCs activated with MAGE-AX, infused every 168 hours during
three weeks (Table 1, Protocol 1) and with the parameters listed in additional mate-
rial (see Additional file 1), the simulation of immunotherapy is realized. In the same
Table 1 Immunotherapy protocol of dendritic cells (DCs)
Infusion time
Protocol week 1 week 2 week 3 week 4 week 5
(0 hrs) (168 hrs) (336 hrs) (504 hrs) (672 hrs)
Control mice Infusion of Mice
6× 104 sacrifice
B16/F10 cells
Protocol 1 Infusion of Infusion of Infusion of Infusion of Mice
(Treatment of DCs with MAGE) 6× 104 106 DC 106 DC 106 DC sacrifice
B16/F10 cells
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Fig. 1 Simulation of tumor growth. Simulation for 700 hours of control mice from T(0) = 6× 104,
r = 0.00106 h−1 and K = 6.75415cells (Table 1)
manner as NRSME is calculated to measure the difference of the tumor growth with-
out immunotherapy we obtain a 10.5% NRMSE between the real population of tumor
cells and the simulated population of tumor cells applying immunotherapy Protocol 1
described in Table 1 (see Fig. 2).
Proposed immunotherapy protocols
Considering the immunotherapy protocol used by the UNAM researchers could be
improve, we suggest different immunotherapy protocols to eradicate the tumor and to
extend the life of mice.
Modification of the amount injected DCs
To test different quantities of injected DCs, we use the same protocol of injection of DCs
in the biologic treatments (three doses each 168 hours in 1000 hours) and we change
the amount of DCs injected per dose. The numerical results are shown in Table 2 (from
Protocol 2 to 9) .
Fig. 2 Simulation of immunotherapy. Simulation applying the immunotheraphy Protocol 1 for 1000 hours,
set to T(0) = 6× 104, r = 0.00106h−1 and K = 6.75415cells (Table 1)
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Table 2 Hypothetical immunotherapy protocol simulated
Protocol DC Inj. Interval Number of % of DCs % of Decrease Erad
doses (hours) doses
2 102 168 3 50 12.61 no
3 103 168 3 50 19.92 no
4 104 168 3 50 20.79 no
5 105 168 3 50 20.95 no
6 106 168 3 50 68.65 no
7 107 168 3 50 88.69 yes
8 108 168 3 50 91.68 yes
9 109 168 3 50 91.68 yes
10 106 48 8 50 85.97 yes
11 106 72 5 50 83.70 yes
12 106 96 4 50 81.40 yes
13 106 120 3 50 76.05 no
14 106 144 3 50 76.72 no
15 106 192 2 50 37.12 no
16 106 216 2 50 33.11 no
17 106 168 3 100 80 yes
18 106 168 3 80 77.58 yes
19 106 168 3 60 73.05 no
20 106 168 3 40 60.33 no
21 106 168 3 20 22.16 no
Inj. Interval Injection Interval, Erad Eradication, % of DCs Percentage of DCs that arrive at the beginning of the immune response.
Tomeasure the efficiency of the proposed protocol, the average reduction of tumor cells
(in percentage terms) is computed comparing the tumor cell population simulated with-
out treatment and the tumor cell population simulated with the hypothetical treatment
measured at the same time (the 7th day after beginning the simulation and every two days
after the 10th day for a period of 1000 hours).
Figures 3 and 4 show some of the simulation results from immunotherapy protocol
proposals where the amount of DCs injected is changed. Figure 3, shows numerical results
considering injections of 1 ∗ 103 DCs every 7 days during 3 weeks (dotted line) it can be
observed that the growth of the tumor does not suffer any change and continues growing,
demonstrating that this amount is not sufficient to eliminate or to detain the growth of
the tumor (thick line) in the simulation.
On the other hand, Fig. 4 shows the results of the 1∗108 DCs injected every 7 days dur-
ing 3 weeks; the simulation shows how the tumor cells population declines dramatically
after 700 hours.
Modification of the immunotherapy interval
It is proposed to modify the infusion interval time of the DCs, conserving the same num-
ber of DCs used in the biological experiment (106 DCs per dose, Protocol 1), to show the
influence of the number of infusions in the treatment. As in the other experiments, the
efficiency of the hypothetical protocol is measured using the average reduction of tumor
cells. The numerical results are shown in Table 2 (from Protocol 10 to 16).
From the results shown in Table 2 it can be observed that the tumor is eradicated for
intervals of injection less than 120 hours in a range of 1000 hours of simulation.
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Fig. 3 Simulation of immunotherapy for different amounts of DCs per dose. Interval injection every 168
hours during three weeks and applying 103 DCs per dose (Table 2, Protocol 3), a 19.92% of decrease was
obtained. Tumor population (thick line) and amount of DCs injected (dotted line) are shown
Figures 5 and 6, show how the immunotherapy is more efficient if the interval of injec-
tion is reduced and the number of injections increased. Applying only one more dose and
reducing the injection interval of 168 hours to 120 hours the simulation shows that the
tumor is eradicated.
Modification of DCs doses and the applied immunotherapy interval
Doses of 102, 103, 104, 105, 106, 107, 108 and 109 DCs were tested with injected intervals of
48, 72, 96, 120, 144, 168 and 192 hours. The results indicate that the tumor is eradicated
for all protocols of DCs doses bigger than 107.
Using doses of 106 DCs with intervals less than 120 hours in a time period of 1000 hours,
the tumor is eradicated. Nevertheless, for intervals of injection longer than 120 hours, the
tumor cells survive after 1000 hours. In the case where the doses are less than 106 DCs,
the tumor cells population continued growing.
Percentage of DCs that induce the immune response
To find out the importance of the percentage of DCs that reach the lymph nodes, the
immunotherapy protocol used by the research group of UNAM is simulated changing the
percentage of DCs injected per doses.
Fig. 4 Simulation of immunotherapy for different amounts of DCs per dose. Interval injection every 168
hours during three weeks and applying 108 DCs per dose (Table 2, Protocol 8) with a 88.69% of decrease
calculated. Tumor population (thick line) and amount of DCs injected (dotted line) are shown
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Fig. 5 Simulation of immunotherapy changing the number of DCs doses. Interval injection every 48 hours
applying 106 DCs per dose during three weeks (Table 2, Protocol 10) a 85.97% of decrease was obtained.
Tumor population (thick line) and amount of DCs injected (dotted line) are shown
The numerical simulation show that if the percentage of DCs arriving at the lymph
nodes increases up to 80%, the tumor is eradicated (see Table 2 from Protocol 17 to 21).
TGF − β cytokine importance
To discover the effect of the TGF − β cytokine in the immunotherapy, the model elimi-
nating the influence of the TGF − β in the immunotherapy were tested. The results show
that the effect of TGF − β in the model increases the tumor cell population. Eliminating
the TGF − β influence, the population of tumor cells is reduced 77.48% and the tumor
could be eradicated (Fig. 7).
Model sensitivity
In order to know which parameters affect the model outcome a local parametric sensitiv-
ity analysis (LPSA) was made [16, 19]. The sensitivity of a single parameter was calculated
by comparing the difference between the final number of tumor cells obtained upon
changing in ±1% the reference value of the parameter to the final number of tumor
cells obtained using the references values of the parameters (Protocol 2, time simulation
1000 hours).
Fig. 6 Simulation of immunotherapy changing the number of DCs doses. Interval injection every 192 hours
applying 106 DCs per dose during three weeks (Table 2, Protocol 15) a 37.12% of decrease was obtained.
Tumor population (thick line) and amount of DCs injected (dotted line) are shown
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Fig. 7 Effect of the TGF − β cytokine in the immunotherapy. Interval injection every 168 hours applying 106
DCs per dose during three weeks. Tumor population (green line) considering the influence of TGF − β in the
model and tumor population (red line) without influence of TGF − β in the model
Figure 8, shows a graphic with the results obtained from the sensitivity analysis. It can
be seen that the parameter “τ ” has the bigger percentage change in the amount of tumor
cells at the end of the model simulation with an interval of change between−76.64% and
45.33%, followed by the tumor growth rate “r” and the maximal efficiency of cytotoxic
cells “aT”.
Discussion
The mathematical model of 5 DDEs presented is capable of simulating the tumor cells
growth with a NRMSE 10% between the results obtained from the model simulation and
real immunotherapy data from the biological trials developed by the UNAM researchers.
In spite of only taking into account the interactions between the tumor cells, the dendritic
cells, the CTLs activated/inactivated and the TGB− β cytokine the approximation could
be considered successful.
The validation of the model allows to test different hypothetical immunotherapy
protocol changing the number of infusions or varying the amount of DCs injected.
Fig. 8 Local Parameters Sensitivity Analysis(LPSA) for the immunotherapy model using the protocol 1
(Table 1)
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As a result of these trials, it is observed that if 4 doses of 106 DCs are injected every 96
hours during 3 weeks, the growth of the tumor is less than the current immunotherapy
protocol and as a result the mice could live longer. This protocol is viable biologically and
experimentally, which could be tested by the research group of UNAM.
By varying the number of DCs injected from the protocol proposed in Table 2, we found
that injecting over 107 dendritic cells the tumor is eradicated. Moreover, increasing this
amount the DCs in vitro is not experimentally viable at themoment for the research group
of UNAM due to laboratory limitations.
In case of variation in the percentage of DCs that induce the immune response,the
objective is to know whether the number of DCs injected affects the therapy efficiency.
The validation model takes into account that not all DCs become effective, around 50%
activated and stimulated the reproduction of the CTLs. By performing this experiment,
the results show that if more that 80% of DCs arrive at the lymph nodes, the tumor is
eradicated. This suggests that if the immunotherapy is improved, making more tumor
cells reach the lymph nodes, the tumor could be erradicated.
Currently, some immunotherapies have been including inhibition of “TGF-β” cytokine
[20], for these reason a hypothetical therapy is suggested in which the effect of this
cytokine is eliminated. In this case the results show that the cytokine has a high relevance
in the effectiveness of the immunotherapy. A combination of infusion of DCs and the
inclusion of inhibitors on the activity of “TGF-β” can give better results than the current
therapy used.
By performing the sensitivity analysis of the parameter model it was observed that the
delay in the time is the most sensitive parameter. Observing in the biological experi-
ment results the main inmunotherapy response is given on the 30th day after injecting
DCs into the mice and not on the day when they were injected. The reason for this
delay is not clear for the UNAM researchers but it is proposed in the model that the
activation and the proliferation of the CTLs was before the CTLs could eliminate the
tumor cells this represents the time delay used in the model. The rate of tumor growth
is another sensitive parameter and is influenced by the type of cancer (in this case skin
melanoma).
On the other hand, the cytotoxity of the CTLs represent the capacity of the CTLs to
eliminate the tumor cells and its other sensitivity parameter. One factor more in the sen-
sitivity of the model is the efficiency of the immunotherapy that means the number of
dendritic cells that arrive at the lymph nodes to activate and reproduce the CTLs. This
efficiency is related with the treatments that the DCs receive before being injected into
the mice, and they are not considered in this model for the moment.
For now there is no biological proof to verify the hypothetical treatment. However, the
objective of the model is to present a guide for a possible therapy with a greater possibility
of success. Future work concerns amplifying the model including more population cells,
cytokines or the treatment of DCs before beginning the immunotherapy.
Conclusions
Themodel represents a simple view of somemechanisms that occur between the immune
system and the immunotherapy with DCs for the melanoma in mice. Even when is
only taking into account 5 interactions between the immune cells, tumor cells and one
cytokine, the model reproduces in an adequate form the behaviour observed in the
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experimental biological trials and its validation gives the possibility to prove different
hypothetical protocols.
Using the model as a framework the numerical results show that immunotherapy used
in the biological experiments could be improve manipulating the number of DCs infused,
changing the intervals of injection, changing the effect of “TGF-β” cytokine or increasing
the percentage of DCs that arrive to the lymph nodes.
Moreover, the model is used to analyse the consequences of manipulating their param-
eters. It is found that the delay in the time “τ ”, the maximal growth rate of the tumor “r”
and maximal efficiency of cytotoxic cell parameter “aT ” plays a significant role in increas-
ing the effectiveness of the immunotherapy. These results give other hints of how the
immunotherapy could be improved.
The the mathematical model can be used as a guide to improve the immunother-
apy and thus minimize the costs in time and money to test new protocols. Even-
tually, the UNAM researchers could have a better possibility of success for a new
protocol.
Finally, during the test phase it was observed that the model could be improved by
increasing the number of key elements for example the CD4+ helper T lymphocyte
response and the B cell response that are related with the production of antibodies with
affinity to recognize the antigen melanoma, the secretion of IL-2 cytokine that acts on
the activated lymphocytes and stimulates their proliferation, the major histocompatibility
complex (MHC) molecules, which are expressed on the surface of the dendritic cells and
stimulate the response of the T cells or include a small pre-treatment DCs model in the
five DDEs of the model.
Methods
Immunotherapy
For the biological experiments, the research group used 10male miceC57BL/6 between 6
and 8 weeks of age maintained in the animal facilities of the Medicine Faculty of UNAM.
DCs used in the immunotherapy are taken from mice bone marrow and incubated in
vitro with MG-CSF cytokine to differentiate the DCs and MAGE-AX (25µ g/ml) antigen
to stimulate the immune response. On the other hand, the formation of melanomas is
induced in mice after infusion 6×104 cell B16/F10 line. Immunotherapy begins in the 10
mice one week latter after the tumor is induced; vaccine protocol uses 106 dendritic cells
per dose infused once a week for 3 weeks (Table 1).
The immunotherapy control was made injecting 6 × 104 tumor melanoma cells in 10
mice (control mice) and allowing the tumor growth without immunotherapy. The effi-
ciency of the biological treatment wasmeasured by comparing tumor diameters, the IL−2
and IL−10 cytokines modulation, the expression of MHCmolecules and the survival rate
of mice receiving the inmunotherapy.
The tumor diameter was measured on day 7 once the tumor cells had been injected.
Afterwards, they were measure every two days consecutively after day 10 until the mice
died or 5 weeks after the first dose of the DCs had been injected.
The results demonstrated that the mice without immunotherapy lived for 28 days, hav-
ing an average diameter of 4.3cm. Injecting the DCs pretreated withMAGE−AX peptide
before the immunotherapy, the outcome showed that some mice lived until the 40th day
with an average diameter of 1.5cm.
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Considering the investigation observation of the research group of UNAM that not
all of DCs could arrive at the lymph nodes to activate the cytotoxic cells, it takes in
consideration that only the 50% of total DCs injected per dose activated the immune
response.
Mathematical model
The proposed model gives a simplified view of the mechanism between the immune
system and the immunotherapy developed by the research group at the Medicine
Faculty of UNAM, where melanoma in mice is treated with a DCs immunotherapy. The
immunotherapy protocol (Table 1) applies three doses of 106 dendritic cell activated with
MAGE-AX, infused every 168 hours during four weeks.
The mathematical model is based on the mathematical model proposed by Kronik
et al. [21] which describes Glioma and Immune system interactions. They define an ordi-
nary differential equations (ODEs) system to simulate ex vivo active alloreactive cytotoxic
T-lymphocytes (aCT) treatment to boost the immune response.
DDEs system is proposed taking into account the interactions between the tumor
cells population “T”, dendritic cells “D”, effector and naive cytotoxic T cells “Ca,
Ci” and the cytokine transforming growth factor β “Fβ”; this cytokine reduces the
efficiency of the immunotherapy, as is shown in [11]. Moreover, the remarks and
conclusions made by the research group of UNAM about their treatment are con-
sidered as well as that only the activated CTLs can eliminate the tumor cells and
these cells produce the transforming growth factor β (TGF-β). A delay in the
time, “τ ” is included in the model to describe the time of activation of dendritic
cells.
Some parameters are obtained from the bibliography, and others are calculated using
the model of DDEs, adjusting their values to biological treatments results, trying to
minimize the difference of the numerical data with the experimental data, see the
supplementary material for a complete explanation.
Mathematical equation
Tumor cells, “T”
To study the growth of tumor cells population “T”, Gompertz growth law was consid-
ered (it provides a better fit to the experimental data than the logistic law) first term
on the right hand side (RHS) of Eq. 1, where the parameter “r” represents the maximal
tumor growth rate and the parameter “K” its carrying capacity (the limit of the maximum
population size of the tumor cells that the environment can sustain). Notice that the num-
ber of cells in a mouse is significantly lower than “K”, we consider Gompertz growth if
T < 1.6× 1010 and the experiments stop if T = 1.6× 1010. It is worth to mention, that at
if T = 1.6×10 the mice died.
For the elimination of tumor cells by the CTLs, “Ca” (second term on the RHS of Eq.1),
it is assumed that both “T” and “Ca” are proportional, the maximal efficiency rate of CTLs
is denoted by “aT ”.
The influence of TGF-β cytokine, “Fβ”, is also considered. It produces a reduction of
immunotherapy efficiency and it is assumed to be an immunosuppresive factor of CTLS
activity, Michaelis-Menten form represented by the factor aT ,β + eT ,β (1−aT ,β )eT ,β+Fβ is used for
that purpose. Where “eT ,β” is the Michaelis-Menten constant and the maximal reduction
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effect of TGF-β on CTLs efficiency is “aT ,β”. This term is similar to that used by Kronik
et al. [21].
dT
dt = rT ln
(K
T
)
− aT · Ca · T ·
(
aT ,B + eT ,B(1− aT ,B)eT ,B + Fβ
)
(1)
Dendritic cells, “D”
Equation 2, describes the population of the dendritic cells dynamics, “D”. The initial num-
ber of dendritic cells is consider, d0 which decay at constant rate µD, then, for n < 168
the number of dendritic cells is given by
D(t) = 0 if t < 168
at tn = n · 168 for n = 1 · · · 3, 106 dendritic cells are injected into the mouse, so, the
number of dendritic cells of the immunotherapy is given by
D(t) :=

0, if t < 168
106e−µD(t−168) · ef , if 168 ≤ t < 168 · 2
106
(
e−µD(t−168) + e−µD(t−168·2)) · ef , if 168 · 2 ≤ t < 168 · 3
106
(
e−µD(t−168) + e−µD(t−168·2) + e−µD(t−168·3)) · ef , if t ≥ 168 · 3.
Where, ef represents the percentage of the DCs which arrive the lymph nodes to begin
the immune response. Notice that the evolution of dendritic cells inside the intervals
(168(n− 1), 168n) for n = 1 · · · 3 is given by
dD
dt = −µDD, t ∈ (168(n− 1), 168n) for n = 1 · · · 3 (2)
Cytotoxic T lymphocyte activated, “Ca”
The dynamic of CTLs activated, “Ca”, is described in Eq. 3 considering the activation of
naive CD8+, expansion of the CTLs activated and a natural death of CTLs activated.
The first term on the right side of the equation represents the cytotoxic cells activation.
It is considered that the contact between the DCs and the inactive cytotoxic cells produce
the activation of these. It is proposed that the activation is made before the death of the
tumor cells and gives a rate ra, The encounter between the inactivated cytotoxic cells and
DCs occurs at the time of t− τ . On the other hand, the survival probability of the inactive
cytotoxic cells during the delay time is considered by the term e−µci τ of the equation 3.
It is assume that the effect of the dendritic cells in the activation of the CTLs follows a
Michaelis-Menten saturation dynamic with a constant of “θD”.
The second term on the right side of the equation represents the expansion of the acti-
vated cytotoxic cells. This expansion shows a rate of re, given for the contact between
the DCs and the activated cytotoxic cells (described as a saturation function of type
Michaelis-Menten). In the same way as the cytotoxic activation cells, the expansion is
given before the death of the tumor cells and occurs at the contact time of t − τ between
the DCs and the activated cytotoxic cells. The probability of the activated cytotoxic cell
survival is consider during the time delay in term e−µca τ of the equation 3.
The natural death of the activated cytotoxic cells is included in the last term of the
equation 3, with a constant death rate “µCa”.
dCa
dt = ra · e
(−µCi τ ) · Ci(t − τ ) ·
( D(t − τ )
D(t − τ )+ θD
)
+re · e(−µCa τ ) · D(t − τ ) ·
( Ca(t − τ )
Ca(t − τ )+ θa
)
− µCaCa. (3)
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Cytotoxic T lymphocyte inactivated, “Ci”
Equation 4, express the inactivated cytotoxic cells dynamic of the population “Ci”. The
first term on the right hand side of the equation is equal to the first term of the equation 3
and represents the decrease of the inactivated cytotoxic cells which will be activated. The
contact between these populations occur in the time t − τ .
Due to the mice immune system not presenting any response before being injected
by immunotherapy, it is not considered a term that produces new inactivated cytotoxic
cells. The model only takes into account a base amount of inactivate cytotoxic cells that
is introduced into the model as an initial condition (see Additional file 1).
The effect of dendritic cells in the CTLs activation is supposed following a Michaelis-
Menten dynamic and the dependence of “Ci” efficiency on “D” population is represented
by Michaelis constant “θD”.
A constant death rate “µCi” is assumed for the cytotoxic inactivated cells.
dCi
dt = −ra · e
(−µCi τ ) · Ci(t − τ ) ·
( D(t − τ )
D(t − τ )+ θD
)
− µCiCi (4)
Transforming growth factor, “Fβ”
Equation 5, describes the cytokine dynamic of TGF-β , “Fβ”. The term “aT ,β” represents
the production rate per tumor cell. It is proportional to the number of tumor cells, “T”.
The last term of the equation is a natural degradation rate “µβ” of the TGF-β .
dFβ
dt = aT ,βT − µβFβ (5)
Computer simulation
The model is implemented using a 4th order Runge Kutta method with the integration
step of 1 hour [22, 23]. Some parameters had been obtained from literature and oth-
ers had been calculated using the model and based on in vivo experimental results of
immunotherapy developed by the research group. The additional material presents the
references used to obtain the model parameters (see Additional file 1).
The experiment data is used to calculate the value of maximal growth rate of tumor, “r”
and the maximal population size of the tumor cells that the environment can sustain “K”
using least square method and setting an initial population size of tumor cells at 6 ∗ 104
according the immunotherapy protocol applied by the research group of UNAM (Table 1).
The maximal efficiency of cytotoxic cells “aT ”, the activation rate of CTLs “ra”, the
expansion rate of activated CTLs “re” and the delay in the time “τ ” are calculated after
an exhaustive search minimizing the difference between the numerical results and the
experimental data, the additional material shows more detail (see Additional file 1).
Additional file
Additional file 1: Description of parameters used in the mathematical model.
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